PARICALCITOL

Paricalcitol is a selective vitamin D receptor agonist that suppresses parathyroid hormone synthesis with relatively less effect on calcium and phosphate absorption. It is used in secondary hyperparathyroidism associated with chronic kidney disease. Benefits include better PTH control and bone metabolism. Side effects include hypercalcemia, hyperphosphatemia, pruritus, GI symptoms, and potential vascular calcification if mineral balance is not carefully monitored.

SKU: 8ff24ee99665 Category: Tag:

Product Description


Mechanism of Action

PARICALCITOL (ID 27026) exhibits a multidimensional biochemical activity profile involving modulation of enzyme-catalyzed pathways, receptor-mediated intracellular signaling, ion-channel regulation, mitochondrial bioenergetics, oxidative-stress balancing, membrane dynamics, and transcription-factor orchestration. Its molecular configuration allows high-affinity interaction with catalytic residues, allosteric domains, regulatory scaffolds, and signaling intermediates, influencing phosphorylation cycles, second‑messenger flux (Ca²⁺, cAMP, IP₃, DAG), ROS equilibrium, ATP synthesis, and mitochondrial respiratory-chain regulation.

Depending on dose, exposure duration, and cell type, PARICALCITOL can modify chromatin accessibility, metabolic flux routing, vesicular trafficking, cytoskeletal structure, and gene-expression clusters associated with survival, inflammation, apoptosis, autophagy, and metabolic adaptation.

Benefits and Advantages

Due to its consistent mechanistic behavior, this compound is utilized in advanced research, including:

  • Receptor–ligand interaction studies and affinity modeling
  • High‑resolution enzyme kinetics and catalytic-pathway deconstruction
  • Mitochondrial ATP‑flux assays and oxidative‑stress system modeling
  • Multi‑omics profiling (transcriptomics, proteomics, metabolomics, phosphoproteomics)
  • Cytoskeletal and membrane‑dynamics exploration
  • Apoptosis, ferroptosis, necroptosis, and autophagy pathway analysis
  • Structure–activity relationship (SAR) investigations and compound optimization
  • Pharmacodynamic modeling, mechanistic dose–response scaling, and pathway benchmarking

Side Effects and Risks

Potential laboratory risks include:

  • Oxidative‑stress imbalance and ROS accumulation
  • Mitochondrial overload or respiratory-chain suppression
  • Ion‑channel dysregulation affecting Ca²⁺/Na⁺/K⁺ homeostasis
  • Unintended receptor cross‑activation or pathway inhibition
  • Cytoskeletal destabilization and membrane‑integrity disruption
  • Dose-dependent cytotoxicity (apoptotic or autophagic induction)
  • Transcriptional or epigenetic instability under prolonged exposure
  • Activation of inflammatory signaling networks (NF‑κB, JNK, p38 MAPK)

Use strictly in controlled laboratory environments with appropriate biosafety protocols.

Datasheet


Molecular Formula

C27H44O3

Molecular Weight

416.6 g/mol

CAS Number

131918-61-1

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

6.80e-03 g/L

Purity

Purity information is available upon request (COA).

Synonym

Paricalcitol; 131918-61-1; Zemplar; Compound 49510; 19-Nor-1alpha,25-dihydroxyvitamin D2

IUPAC/Chemical Name

trans-(1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol

InChl Key

BPKAHTKRCLCHEA-UBFJEZKGSA-N

InChl Code

InChI=1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/5281104;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download